WO2007034507A3 - Tetravalent dengue specific domain iii based chimeric recombinant protein - Google Patents

Tetravalent dengue specific domain iii based chimeric recombinant protein Download PDF

Info

Publication number
WO2007034507A3
WO2007034507A3 PCT/IN2006/000316 IN2006000316W WO2007034507A3 WO 2007034507 A3 WO2007034507 A3 WO 2007034507A3 IN 2006000316 W IN2006000316 W IN 2006000316W WO 2007034507 A3 WO2007034507 A3 WO 2007034507A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue
domain iii
protein
virus type
recombinant protein
Prior art date
Application number
PCT/IN2006/000316
Other languages
French (fr)
Other versions
WO2007034507A2 (en
Inventor
Gaurav Batra
Menaka Hapugoda
Suchita Chaudhry
Sathyamangalam Swaminathan
Navin Khanna
Original Assignee
Icgeb
Gaurav Batra
Menaka Hapugoda
Suchita Chaudhry
Sathyamangalam Swaminathan
Navin Khanna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icgeb, Gaurav Batra, Menaka Hapugoda, Suchita Chaudhry, Sathyamangalam Swaminathan, Navin Khanna filed Critical Icgeb
Publication of WO2007034507A2 publication Critical patent/WO2007034507A2/en
Publication of WO2007034507A3 publication Critical patent/WO2007034507A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A single recombinant Tetravalent Domain III (rTDIII) protein for use in the detection and or diagnosis of any or all of dengue specific Immunoglobin M anti- dengue IgM and Immunoglobin G anti-dengue IgG antibodies is disclosed. Said protein comprises domain III of envelope protein from all four serotypes of dengue virus, namely, Dengue-virus type-1, Dengue-virus type-2, Dengue-virus type-3 and Dengue- virus type-4, linked with each other through penta glycine linkers and codon optimized for expression in an expression vector. The protein of the presentb invention shows a very high degree of sensitivity and specificity to anti-dengue IgM and anti-dengue IgG antibodies.
PCT/IN2006/000316 2005-09-20 2006-08-30 Tetravalent dengue specific domain iii based chimeric recombinant protein WO2007034507A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2539DE2005 2005-09-20
IN2539/DEL/2005 2005-09-20

Publications (2)

Publication Number Publication Date
WO2007034507A2 WO2007034507A2 (en) 2007-03-29
WO2007034507A3 true WO2007034507A3 (en) 2007-06-21

Family

ID=37735120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000316 WO2007034507A2 (en) 2005-09-20 2006-08-30 Tetravalent dengue specific domain iii based chimeric recombinant protein

Country Status (1)

Country Link
WO (1) WO2007034507A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152652A2 (en) * 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology A dengue envelope domain iii-based tetravalent protein vaccine
MX2010007461A (en) * 2008-01-11 2010-10-20 VGX Pharmaceuticals LLC Novel vaccines against multiple subtypes of dengue virus.
WO2012045063A2 (en) * 2010-10-01 2012-04-05 University Of Rochester Flavivirus domain iii vaccine
ITRM20130458A1 (en) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And ANTI-DENGUE VIRUS GENETIC VACCINE BASED ON THE ECTODOMINS OF THE PROTEIN ENVELOPE
NO340722B1 (en) * 2014-06-27 2017-06-06 Norwegian Institute For Agricultural & Environmental Res Transgenic plants expressing a recombinant tetravalent chimeric dengue virus antigen to produce effective vaccines derived therefrom, as well as transgenic plastid, plant cell and seeds, recombinant DNA molecule, vector, methods of preparation and use thereof
ES2821480T3 (en) * 2014-09-01 2021-04-26 Int Centre For Genetic Engineering And Biotechnology Vaccine
CN106771123A (en) * 2016-12-14 2017-05-31 苏州万木春生物技术有限公司 A kind of preparation method of dengue virus IgM/IgG antibody Test paper
CN107014994A (en) * 2016-12-23 2017-08-04 苏州万木春生物技术有限公司 A kind of preparation method of antibody of HCV Test paper

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006068A2 (en) * 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
WO1999009414A1 (en) * 1997-08-14 1999-02-25 Institut Pasteur Use of recombinant envelope proteins for diagnosing the dengue virus
WO2005014627A1 (en) * 2003-08-07 2005-02-17 International Centre For Genetic Engineering And Biotechnology Recombinant dengue multi epitope proteins as diagnostic intermediates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006068A2 (en) * 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
WO1999009414A1 (en) * 1997-08-14 1999-02-25 Institut Pasteur Use of recombinant envelope proteins for diagnosing the dengue virus
WO2005014627A1 (en) * 2003-08-07 2005-02-17 International Centre For Genetic Engineering And Biotechnology Recombinant dengue multi epitope proteins as diagnostic intermediates

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANANDARAO R ET AL: "A custom-designed recombinant multiepitope protein as a dengue diagnostic reagent", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 41, no. 1, May 2005 (2005-05-01), pages 136 - 147, XP004840050, ISSN: 1046-5928 *
CHATURVEDI U C ET AL: "Dengue vaccines: problems and prospects.", THE INDIAN JOURNAL OF MEDICAL RESEARCH MAY 2005, vol. 121, no. 5, May 2005 (2005-05-01), pages 639 - 652, XP002421668, ISSN: 0971-5916 *
JAISWAL S ET AL: "High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 33, no. 1, January 2004 (2004-01-01), pages 80 - 91, XP004475016, ISSN: 1046-5928 *
KHANAM SAIMA ET AL: "Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes", AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 74, no. 2, February 2006 (2006-02-01), pages 266 - 277, XP002421333, ISSN: 0002-9637 *
SIMMONS M ET AL: "SHORT REPORT: ANTIBODY RESPONSES OF MICE IMMUNIZED WITH A TETRAVALENT DENGUE RECOMBINANT PROTEIN SUBUNIT VACCINE", AMERICAN JOURNAL OF TROPICAL MEDICINE & HYGIENE, LAWRENCE, KS, US, vol. 65, no. 2, August 2001 (2001-08-01), pages 159 - 161, XP009015135, ISSN: 0002-9637 *
SWAMINATHAN S ET AL: "Viral vaccines for dengue: The present and the future", DENGUE BULLETIN, WHO REGIONAL OFFICE FOR SOUTH-EAST ASIA, NEW DELHI, IN, vol. 27, 2003, pages 181 - 191, XP002331688, ISSN: 1020-895X *

Also Published As

Publication number Publication date
WO2007034507A2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2007034507A3 (en) Tetravalent dengue specific domain iii based chimeric recombinant protein
Abe et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2
Petracca et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding
Moschioni et al. The two variants of the Streptococcus pneumoniae pilus 1 RrgA adhesin retain the same function and elicit cross-protection in vivo
Moreland et al. High affinity human antibody fragments to dengue virus non-structural protein 3
NZ596865A (en) Single-chain multivalent binding proteins with effector function
Lisova et al. Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus
Sabo et al. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature
RO115471B1 (en) Method for determining one or more types of hepatitis c virus
NZ506553A (en) Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of hcv viral antigen in host tissue
Shelton et al. Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction
Zhou et al. Positive reactions on Western blots do not necessarily indicate the epitopes on antigens are continuous
Rizzo et al. Selection and characterization of highly specific recombinant antibodies against West Nile Virus E protein
Zhang et al. Recombinant DENV 2 NS5: an effective antigen for diagnosis of DENV infection
CN104744572A (en) Avian and porcine hepatitis e virus shared antigen, monoclonal antibody and preparation method and application
Park et al. Combination of cysteine-and oligomerization domain-mediated protein immobilization on a surface plasmon resonance (SPR) gold chip surface
BR0314166A (en) Hcv test
Kota et al. Peptide inhibitors of hepatitis C virus core oligomerization and virus production
Alhammad et al. Longitudinal sequence and functional evolution within glycoprotein E2 in hepatitis C virus genotype 3a infection
CN104311654A (en) CIDE3 polypeptide, preparation of antibody thereof and applications of the antibody
Kim et al. Built‐in RNA‐mediated chaperone (chaperna) for antigen folding tailored to immunized hosts
WO2005014627A1 (en) Recombinant dengue multi epitope proteins as diagnostic intermediates
Daxecker et al. A peptide affinity column for the identification of integrin αIIb-binding proteins
Uddin et al. Single‐step purification of cyclotides using affinity chromatography
Lee et al. Novel short peptide tag from a bacterial toxin for versatile applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06809937

Country of ref document: EP

Kind code of ref document: A2